APA (7th ed.) Citation

Fernández Montes, A., Martinez Lago, N., De la Cámara Gómez, J., Covela Rúa, M., Cousillas Castiñeiras, A., Gonzalez Villarroel, P., & Méndez Méndez, J. (2019). P-089 - FOLFIRI plus panitumumab as second-line treatment in mutated RAS metastatic colorectal cancer patients who converted to wild type RAS after receiving first-line FOLFOX/CAPOX plus bevacizumab-based treatment: Phase II CONVERTIX trial. Annals of Oncology, 30, iv23. https://doi.org/10.1093/annonc/mdz155.088

Chicago Style (17th ed.) Citation

Fernández Montes, A., N. Martinez Lago, J. De la Cámara Gómez, M. Covela Rúa, A. Cousillas Castiñeiras, P. Gonzalez Villarroel, and J. Méndez Méndez. "P-089 - FOLFIRI Plus Panitumumab as Second-line Treatment in Mutated RAS Metastatic Colorectal Cancer Patients Who Converted to Wild Type RAS After Receiving First-line FOLFOX/CAPOX Plus Bevacizumab-based Treatment: Phase II CONVERTIX Trial." Annals of Oncology 30 (2019): iv23. https://doi.org/10.1093/annonc/mdz155.088.

MLA (9th ed.) Citation

Fernández Montes, A., et al. "P-089 - FOLFIRI Plus Panitumumab as Second-line Treatment in Mutated RAS Metastatic Colorectal Cancer Patients Who Converted to Wild Type RAS After Receiving First-line FOLFOX/CAPOX Plus Bevacizumab-based Treatment: Phase II CONVERTIX Trial." Annals of Oncology, vol. 30, 2019, p. iv23, https://doi.org/10.1093/annonc/mdz155.088.